Deltex Medical Regulatory News (DEMG)

23 Jan 2008 07:01

Deltex Medical Group PLC23 January 2008 Deltex Medical Group plc Positive scientific review of CardioQ technology published 23 January 2008 - Deltex Medical Group plc ("Deltex Medical"), the UK's leadinghaemodynamic monitoring company, today announces the results of a new review ofthe CardioQ(TM) technology of oesophageal Doppler monitoring (ODM). The paper from doctors at the University of Auckland in New Zealand waspublished in the journal Anaesthesia and assesses, using the technique ofmeta-analysis, the clinical evidence for the use of ODM in abdominal surgery.Meta-analysis (a systematic scientific review which considers related evidenceas a whole) is used heavily by doctors within clinical circles to determinetechnologies and interventions which should be established as standards of care. The meta-analysis concluded that "Pooled analysis showed a reduced hospital stayin the intervention group. Overall, there were fewer complications and ICUadmissions, and less requirement for inotropes (drugs used to enhance theheart's performance) in the intervention group. Return of normalgastro-intestinal function was also significantly faster in the interventiongroup. Oesophageal Doppler use for monitoring and optimisation of flow-relatedhaemodynamic variables improves short-term outcome in patients undergoing majorabdominal surgery." The full article (S. M. Abbas, A. G. Hill (2008): Systematic review of theliterature for the use of oesophageal Doppler monitor for fluid replacement inmajor abdominal surgery Anaesthesia 63 (1), 44-51) is available to subscribersat http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2044.2007.05233.x Deltex Medical's Chief Executive, Andy Hill commented: "This is the first meta-analysis on ODM to have been published in apeer-reviewed scientific journal. Its publication only reinforces that theCardioQ is closer than ever before to being widely acknowledged as a standard ofcare." For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6000(Nominated Adviser)Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ(TM) monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already around 1,500 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange